Pro Medicus (ASX:PME) has had a great run on the share market with its stock up by a significant 28% over the last three months. Since the market usually pay for a company’s long-term fundamentals, we ...

Pro Medicus Limited ( ($AU:PME) ) just unveiled an announcement. Pro Medicus Limited has disclosed a small on-market share purchase by ...

Pro Medicus (ASX:PME) is currently experiencing a mix of strong growth and significant market challenges. Recent developments include a 29.3% revenue increase and a 36.5% rise in profit after tax, ...

Pro Medicus Ltd. Annual stock financials by MarketWatch. View the latest PME financial statements, income statements and financial ratios.

The average one-year price target for Pro Medicus (ASX:PME) has been revised to 76.25 / share. This is an increase of 6.31% from the prior estimate of 71.72 dated August 31, 2023. The price target is ...

Fintel reports that on April 7, 2025, BELL POTTER SECURITIES downgraded their outlook for Pro Medicus (ASX:PME) from Buy to Hold. As of April 2, 2025, the average one-year price target for Pro Medicus ...

Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...

Pro Medicus Limited has disclosed a minor change in the shareholding of Director Sam Aaron Hupert, who has increased his direct interest in the company through an on‑market purchase of 2,250 ordinary ...

Pro Medicus Ltd. engages in the development and supply of healthcare imaging software, Radiology Information System (RIS), and services to hospitals. It operates through the following geographical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.